Information Center
Xinkanghe Biopharmaceutical XKH002 completes the first patient dosing in the Phase I clinical trial in China.
Release time:
2023-11-28 16:33
Beijing, China, Suzhou, Jiangsu,Xinkanghe BiopharmaceuticalAs a biopharmaceutical company dedicated to developing independently innovative drugs, it announced today its antiB7S1(B7H4)monoclonal antibody (XKH002) in ChinaPhase I clinical study (numberedXKH002-01-I) completed the first patient dosing on11month27day.
This study is an open-label, dose-escalation,multicenterPhase I dose-escalation study,aimed at evaluatingXKH002the safety, tolerability, and pharmacokinetics in patients with advanced solid tumors.It is led by Professor Shen Lin from Beijing Cancer Hospital (LeadingPI).
Mr. Wang Yaning, CEO of Xinkanghe Biopharmaceutical, stated:"As we all know, PD1/PD-L1-based immunotherapy drugs have played a significant role in cancer treatment, but a large portion of patients are insensitive to these drugs, resulting in a huge unmet therapeutic need. As a global leader in antiB7S1blocking antibody drugs,XKH002it is expected to become a new therapy in the field of immunotherapy. We will fully promote the clinical trials of this project and look forward to providing safer and more effective treatment options for cancer patients in China and abroad, benefiting a wide range of patients.
AboutXKH002
XKH002 is a recombinant anti-B7S1 blocking humanized IgG4 monoclonal antibody independently developed by Xinkanghe Biopharmaceutical. XKH002 can specifically bind to B7S1 and effectively block the B7S1-mediated inhibition ofTcell proliferation and immune response.It helps restore and enhance the body's anti-tumor immune response and has broad-spectrum anti-cancer potential.XKH002About Xinkanghe Biopharmaceutical
Xinkanghe Biopharmaceutical was established in
year, founded by internationally renowned immunologist Academician Dong Chen. The company adheres to the basis of cutting-edge international immunology research, focusing on the development of macromolecular drugs in the fields of autoimmune diseases and immuno-oncology, committed to creating innovative drugs with independent intellectual property rights originating from China for the global market, providing globally innovative or best-in-class treatment solutions for patients. The company upholds the R&D philosophy of "innovation, precision, quality, and focus," combining solid basic science with translational medicine, possessing multiple globally independent intellectual property innovative pipeline products and new indications entering clinical stages. Xinkanghe will continue to delve into the unmet clinical needs in the fields of inflammation,2015autoimmune diseases, and tumor immunotherapy, and is also looking forward to deep cooperation with innovative pharmaceutical companies at home and abroad./自身免疫疾病和肿瘤免疫治疗中临床需求未被满足的领域，也非常期待与国内外创新药企进行深度合作。
xkh002, immunity, b7s1
Related News
Beijing Address: A203, Zhongguancun Biomedical Park, No.5, Development Road, Haidian District, Beijing
Zhejiang Address: Floor 8, Building 7, Dongsheng Huigu, 1299 Kehai Avenue, Keqiao District, Shaoxing City, Zhejiang Province
Contact Phone:010-82176552
E-mail:hr@kanovabiopharma.com